News Bayer moves Hyrnuo into frontline lung cancer treatment Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News Boehringer gets FDA's second 'national priority' approval Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.
News Bayer takes on Boehringer with FDA nod for lung cancer drug Bayer joins Boehringer with FDA approval for a second-line, oral therapy for HER2-positive lung cancer, setting up a marketing battle in the US.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
